NASDAQ:SGTX
Delisted

Sigilon Therapeutics Stock Insider Trading

etoro logo Buy SGTX
*Your capital is at risk
$22.47
+0 (+0%)
At Close: Nov 09, 2023

Sigilon Therapeutics Stock Insider Power

Based on the 0 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 0 and sold 0 SGTX shares in the last 0 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Historical Insider Trades

There is currently no insider trading information for this ticker.

However, we invite you to learn more about this term and how to use this knowledge to benefit your trading strategy:

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT SIGILON THERAPEUTICS, INC.
Sigilon Therapeutics
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged rel...
GOLDEN STAR
Ticker Change Signal Date
IDYA
$28.98
7.87% Jun 12
DHI
$146.71
3.93% Jun 10
PHM
$118.49
2.86% Jun 10
EAT
$140.46
13.06% Jun 05
TPR
$140.47
3.84% Jun 04

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE